HC Wainwright & Co. reiterated coverage on Celyad Oncology with a new price target

8/6/21 6:06:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

HC Wainwright & Co. reiterated coverage of Celyad Oncology with a rating of Buy and set a new price target of $15.00 from $17.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CYAD

Date	Price Target	Rating	Analyst
1/11/2022	$20.00 → $11.00	Overweight	Wells Fargo
8/6/2021	$17.00 → $15.00	Buy	HC Wainwright & Co.